Patents by Inventor De Santis Rita

De Santis Rita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-human tenascin monoclonal antibody
    Patent number: 8048417
    Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: November 1, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: De Santis Rita, Anastasi Anna Maria
  • Anti-human tenascin monoclonal antibody
    Publication number: 20110020219
    Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.
    Type: Application
    Filed: September 17, 2008
    Publication date: January 27, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE
    Inventors: De Santis Rita, Anastasi Anna Maria
  • Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
    Patent number: 7807133
    Abstract: Dimers of avidin and streptavidins (diavidins) are described wherein the linker is suberate, which in turn, is bound to different functional groups (—NH2 o-COOH) of avidin. As compared to avidin, the diavidins have shown the ability to increase the amount of labelled biotin on the target, when used in an in vitro pretargeting test using supported human tenascin, the biotinylated anti-tenascin monoclonal antibody (Mab-B), avidin/diavidin, and biotin-3H. The use of such diavidins is also described in cancer diagnosis and anticancer therapy based on the three-step pretargeted radioimmunotherapy procedure.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: October 5, 2010
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: De Santis Rita, Lindstedt Ragnar, Nuzzolo Carlo Antonio
  • Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
    Publication number: 20090010839
    Abstract: Dimers of avidin and streptavidins (diavidins) are described wherein the linker is suberate, which in turn, is bound to different functional groups (—NH2 o-COOH) of avidin. As compared to avidin, the diavidins have shown the ability to increase the amount of labelled biotin on the target, when used in an in vitro pretargeting test using supported human tenascin, the biotinylated anti-tenascin monoclonal antibody (Mab-B), avidin/diavidin, and biotin-3H. The use of such diavidins is also described in cancer diagnosis and anticancer therapy based on the three-step pretargeted radioimmunotherapy procedure.
    Type: Application
    Filed: July 3, 2008
    Publication date: January 8, 2009
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE
    Inventors: De Santis Rita, Lindstedt Ragnar, Nuzzolo Carlo Antonio
  • Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
    Publication number: 20050106102
    Abstract: Dimers of avidin and streptavidins (diavidins) are described wherein the linker is suberate, which in turn, is bound to different functional groups (—NH2 o-COOH) of avidin. As compared to avidin, the diavidins have shown the ability to increase the amount of labelled biotin on the target, when used in an in vitropretargeting test using supported human tenascin, the biotinylated anti-tenascin monoclonal antibody (Mab-B), avidin/diavidin, and biotin-3H. The use of such diavidins is also described in cancer diagnosis and anticancer therapy based on the three-step pretargeted radioimmunotherapy procedure.
    Type: Application
    Filed: March 6, 2003
    Publication date: May 19, 2005
    Inventors: De Santis Rita, Lindstedt Ragnar, Nuzzolo Carlo Antonio
  • Anti-human tenascin monoclonal antibody
    Publication number: 20050106145
    Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.
    Type: Application
    Filed: February 20, 2003
    Publication date: May 19, 2005
    Inventors: De Santis Rita, Anastasi Anna Maria